Dopamine replacement therapy and deep brain stimulation of the subthalamic nuclei induce modulation of emotional processes at different spatial frequencies in Parkinson's disease.

Deep brain stimulation of the subthalamic nuclei (STN-DBS) is an effective treatment for the most severe forms of Parkinson's disease (PD) and is intended to suppress these patients' motor symptoms. However, be it in association with Dopamine Replacement Therapy (DRT) or not, STN-DBS may in some cases induce addictive or emotional disorders.
In the current study, we suggest that PD patients suffer from emotional deficits that have not been revealed in previous studies because in those experiments the stimuli were displayed for a time long enough to allow patients to have recourse to perceptual strategies in order to recognize the emotional facial expressions (EFE).
The aim of the current article is to demonstrate the existence of emotional disorders in PD by using a rapid presentation of the visual stimuli (200-ms display time) which curtails their perceptual analysis, and to determine whether STN-DBS, either associated or not associated with DRT, has an impact on the recognition of emotions.
The results show that EFE recognition performance depends on both STN-DBS ('on' vs. 'off') and medication ('on' vs. 'off'), but also that these variables have an interactive influence on EFE recognition performance. Moreover, we also reveal how these EFE impairments depend on different spatial frequencies perceptual channels (related to different cortical vs. subcortical neural structures).
The effect of PD without therapy seems to be particularly acute for LSF emotional faces, possibly due to a subcortical dysfunction. However, our results indicate that the joint action of STN-DBS and DRT could also disrupt recognition of emotional expressions at the level of occipito-temporal cortical areas (processing HSF visual information) inducing broad global impairment of EFE at the level of HSF visual channels.
AuthorsMartial Mermillod, Laurie Mondillon, Isabelle Rieu, Damien Devaux, Patrick Chambres, Catherine Auxiette, Hélène Dalens, Louise Marie Coulangeon, Isabelle Jalenques, Franck Durif
JournalJournal of Parkinson's disease (J Parkinsons Dis) Vol. 4 Issue 1 Pg. 97-110 ( 2014) ISSN: 1877-718X [Electronic] Netherlands
PMID24496100 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiparkinson Agents
  • Levodopa
  • Affect (physiology)
  • Aged
  • Antiparkinson Agents (adverse effects)
  • Combined Modality Therapy
  • Deep Brain Stimulation (adverse effects)
  • Emotions (physiology)
  • Facial Expression
  • Humans
  • Levodopa (adverse effects)
  • Middle Aged
  • Parkinson Disease (drug therapy, physiopathology, therapy)
  • Subthalamic Nucleus (surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: